Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases.
Attauabi M, Höglund C, Fassov J, Pedersen KB, Hansen HB, Wildt S, Jensen MD, Neumann A, Lind C, Jacobsen HA, Popa AM, Kjeldsen J, Pedersen N, Molazahi A, Haderslev K, Aalykke C, Knudsen T, Cebula W, Munkholm P, Bendtsen F, Seidelin JB, Burisch J.
Attauabi M, et al. Among authors: jacobsen ha.
Scand J Gastroenterol. 2021 Sep;56(9):1040-1048. doi: 10.1080/00365521.2021.1946588. Epub 2021 Jul 5.
Scand J Gastroenterol. 2021.
PMID: 34224299